A102. THE DEVELOPMENT, PROGRESSION, AND TREATMENT OF ILD

External Validation and Longitudinal Application of a Multidimensional Index to Individualize Survival Prediction in Idiopathic Pulmonary Fibrosis

Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2569 A. Chandel, S. Gupta, J. Galanter, Y. Chen, S. D NATHAN

Conventional Hypersensitivity Pneumonitis Management Vs the Addition of Antifibrotic Therapy: Does It Slow Disease Progression?

Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2582 S. Shah, A. Elshikh, L. Patel, B. Bemiss

Factors Associated With Persistence With Antifibrotic Therapy in Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Pulmonary Fibrosis Foundation Patient Registry

Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2576 T. Kulkarni, K. Flaherty, S. Gupta, Y. Tu, A. Hajari Case